Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#ChronicHepatitisB

Home » #ChronicHepatitisB
AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

Posted by By El Bachir MOURABIT 2024.12.03
From November 15-19, 2024, the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in San Diego, USA. At this prestigious event, Dr.…
Read More
JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs

JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs

Posted by By Peng Longmei 2024.09.17
According to the World Health Organization (WHO), approximately 296 million people globally suffer from chronic hepatitis B (CHB). Despite the advent of new therapies, long-term treatment with nucleos(t)ide analogs (NAs)…
Read More
Dr. Jie Li: Exploring and Prospects of Functional Cure for Chronic Hepatitis B

Dr. Jie Li: Exploring and Prospects of Functional Cure for Chronic Hepatitis B

Posted by By El Bachir MOURABIT 2024.09.08
Editor's Note: Achieving a functional cure for chronic hepatitis B (CHB) has become the recognized ideal treatment goal in both domestic and international guidelines, as it significantly reduces the risk…
Read More
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections

Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections

Posted by By Mourabit Halima 2024.02.16
Currently, there is limited research on the natural history of disease in patients with chronic hepatitis B in the "gray zone," and there is still debate about the necessity of…
Read More
APASL 2023 | Prof. Wu Chao: Metabolic Predictors and Liver Fibrosis Diagnostic Model Construction for Chronic Hepatitis B Combined with NAFLD

APASL 2023 | Prof. Wu Chao: Metabolic Predictors and Liver Fibrosis Diagnostic Model Construction for Chronic Hepatitis B Combined with NAFLD

Posted by By Mourabit Halima 2024.01.03
Editor's Note: Chronic hepatitis B (CHB) is the primary cause of chronic liver disease in China and other Asian countries, as well as a major contributor to liver-related morbidity and…
Read More
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Posted by By Peter W. PENG 2023.12.21
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu…
Read More
Recent Posts
  • Professor Dingwei Ye: Building an Authoritative Academic Platform in Uro-Oncology and Driving Continuous Progress in Urothelial Carcinoma Management |
  • Professor Hao Zeng’s Team Publishes in JAMA Oncology: Innovative First-Line Immunotherapy Approach for Advanced FH-Deficient Renal Cell Carcinoma
  • AI-Driven Imaging Breakthrough in CAR-T Therapy丨Professor Stephen Schuster on Predicting Efficacy
  • Polatuzumab Improves Survival in Relapsed/Refractory DLBCL丨Phase III POLARGO Study Highlights
  • Breakthrough Discovery of LymphoMAPs in Large B-cell Lymphoma丨Professor David Russler-Germain on CAR T Therapy
Recent Comments
    Archives
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top